Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The relationships of classic psychedelic use with criminal behavior in the United States adult population
Peter S. Hendricks, Michael Crawford, Karen L. Cropsey, et al.
Journal of Psychopharmacology (2017) Vol. 32, Iss. 1, pp. 37-48
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 421
Predicting Responses to Psychedelics: A Prospective Study
Eline Haijen, Mendel Kaelen, Leor Roseman, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 322
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks, et al.
Neuropharmacology (2018) Vol. 142, pp. 143-166
Open Access | Times Cited: 268
Violence and mental disorders: a structured review of associations by individual diagnoses, risk factors, and risk assessment
Daniel Whiting, Paul Lichtenstein, Seena Fazel
The Lancet Psychiatry (2020) Vol. 8, Iss. 2, pp. 150-161
Open Access | Times Cited: 212
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 156
Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings
Matthias Forstmann, Daniel Alexander Yudkin, Annayah Miranda Beatrice Prosser, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 5, pp. 2338-2346
Open Access | Times Cited: 148
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Albert Garcia‐Romeu, William A. Richards
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 291-316
Closed Access | Times Cited: 153
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Peter S. Hendricks
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 331-342
Closed Access | Times Cited: 147
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
Grant Jones, Matthew K. Nock
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 46-56
Closed Access | Times Cited: 47
Risk factors for recidivism in individuals receiving community sentences: a systematic review and meta-analysis
Denis Yukhnenko, Nigel Blackwood, Seena Fazel
CNS Spectrums (2019) Vol. 25, Iss. 2, pp. 252-263
Open Access | Times Cited: 64
Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder
Richard J. Zeifman, Anne Catherine Wagner
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 1-11
Closed Access | Times Cited: 61
Associations between lifetime classic psychedelic use and markers of physical health
Otto Simonsson, James Sexton, Peter S. Hendricks
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 447-452
Open Access | Times Cited: 55
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
Grant Jones, Matthew K. Nock
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 57-65
Closed Access | Times Cited: 31
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 31
Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study
Grant Jones, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy
Zach Walsh, Michelle S. Thiessen
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 343-349
Closed Access | Times Cited: 55
Psychedelic use and intimate partner violence: The role of emotion regulation
Michelle S. Thiessen, Zach Walsh, Brian M. Bird, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 7, pp. 749-755
Closed Access | Times Cited: 48
LSD use in the United States: Trends, correlates, and a typology of us
Brittany Killion, Audrey Hang Hai, Abdulaziz Alsolami, et al.
Drug and Alcohol Dependence (2021) Vol. 223, pp. 108715-108715
Closed Access | Times Cited: 40
Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson, Walter Osika, Robin Carhart‐Harris, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 36
Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
Daniel R. George, Ryan Hanson, Darryl Wilkinson, et al.
Culture Medicine and Psychiatry (2021) Vol. 46, Iss. 4, pp. 890-903
Open Access | Times Cited: 33
The economics of psychedelic-assisted therapies: A research agenda
Elliot Marseille, Stefano Bertozzi, James G. Kahn
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 26
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Jack E. Henningfield, Marion A. Coe, Roland R. Griffiths, et al.
Neuropharmacology (2022) Vol. 218, pp. 109220-109220
Open Access | Times Cited: 24
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Haley Maria Dourron, Camilla K. Strauss, Peter S. Hendricks
Pharmacological Reviews (2022) Vol. 74, Iss. 4, pp. 984-1029
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top